DYNAMIKA: Your One Stop for Clinical Trial Imaging.
Designed to accelerate the next wave of drug development for biopharma, CROs, and researchers. An AI-enabled platform that delivers faster, more reliable imaging endpoints, driving regulatory success and accelerating drug development.
One solution for all your clinical trial imaging needs
Streamline imaging workflows and reduce trial delays.
Track site, reader, and CRO performance across all stakeholders in real time.
Leverage consistent, high‑quality imaging data for regulatory submissions.
Improve trial outcomes by eliminating complexity in imaging management.
Let’s Get Started
Our strategic collaborations give biotech and pharma teams access to powerful imaging data, operational excellence, and flexible trial designs, driving the next wave of drug innovation.
Why Partner With Image Analysis Group
Industry-Leading Expertise in Imaging Clinical Trials
IAG brings two decades of global experience in designing and executing imaging endpoints for Phase I-III studies, supporting biotech and pharma companies in oncology, immunology, neurology, and more
Advanced, AI-Powered Imaging Platform DYNAMIKA
Benefit from DYNAMIKA, our award-winning cloud-based platform for imaging data management, central review, and regulatory-grade analytics. Unlock early efficacy, robust safety insights, and transparency across stakeholders—accelerating development and maximizing trial success.
Global Site Network & World-Class Radiology Experts
Tap into IAG’s vast network of imaging sites, expert radiologists, and project managers across North America, EU, UK, India, and China for comprehensive support in both global and regional trials.
Accelerate Trial Timelines & De-Risk Development
With predictive imaging biomarkers and AI-powered endpoints, IAG helps sponsors achieve faster patient recruitment, real-time oversight, and rapid database lock, lowering R&D risks while improving trial outcomes.
Trust, Transparency, and Regulatory Compliance
Work with a partner trusted for hundreds of successful trials since 2007. IAG delivers validated processes, 21CFR Part 11 and ISO 13485 compliance, and transparent access to imaging data for confident regulatory submissions
Contact Us Today
speak to our expert team today
More Information?
What regulatory and data security standards does IAG adhere to?
21 CFR Part 11 compliant imaging platform and SOPs
Image Analysis Group (IAG) operates under rigorous regulatory and data security standards to support successful global drug development. The group combines certified infrastructure with proven regulatory experience to give Sponsors confidence at inspection and at the time of marketing submission.
Regulatory framework
IAG’s imaging platform DYNAMIKA and processes are designed to comply with 21 CFR Part 11 requirements for electronic records and electronic signatures, ensuring data integrity, traceability, and robust audit trails across all imaging workflows.
The organization also maintains SOC 2–aligned controls for security, availability, and confidentiality, demonstrating strong governance around data protection and system reliability.
Inspection readiness and track record
IAG has undergone two intensive mock FDA inspections, using these to stress‑test its quality system, refine documentation, and validate inspection readiness across operations, technology, and clinical delivery. These capabilities have contributed to the execution of pivotal and late‑phase trials whose results supported regulatory submissions and helped bring new products to market, reinforcing IAG’s role as a trusted long‑term partner for Sponsors.
What is Image Analysis Group’s experience in managing imaging for clinical trials?
Central imaging experts and core lab for MRI, Xray, CT, DXA, PET and US
Image Analysis Group (IAG) is a trusted global leader in imaging clinical research, empowering biotech and pharmaceutical companies to accelerate drug development with expert imaging solutions. Since 2007, IAG has delivered over 700 successful trials across all phases, providing end-to-end support from study design and site setup to image acquisition, central review, and regulatory submission.
Our proprietary DYNAMIKA platform streamlines imaging data management with real-time quality control, advanced analytics, and AI-powered endpoints, enhancing trial efficiency and data transparency. IAG’s in-house radiology and therapeutic experts design tailored imaging strategies for oncology, immunology, neurology, rare disease, and more, ensuring your trial’s imaging endpoints deliver maximum value.
With a quality-certified global network and published success in reducing sample sizes and accelerating timelines, IAG offers collaborative, innovation-driven partnerships that de-risk development and speed your product to market.
Partner with IAG to unlock optimal results in your clinical trials.
What is your global reach and presence? In which regions do you operate and support trials?
Phase II/III imaging vendor global reach
Image Analysis Group (IAG) provides truly global imaging clinical trial services, supporting biotech and pharmaceutical clients through operational teams, offices, and partnerships across the UK, EU, USA, India, China, Australia, Africa, and beyond. This global network enables Sponsors to run multi-center trials at qualified imaging sites and achieve rapid, confident study start-up in any region.
Headquartered in London, IAG delivers comprehensive project management for Phase I–III clinical trials and real-world evidence (RWE) studies. With dedicated teams in the USA, UK, EU, and India, and partner teams in China, we ensure seamless execution, strong local insight, and responsive communication.
Our extensive network of imaging sites and expert readers guarantees consistent, high-quality data collection around the world. Reach out to discuss imaging site networks and reader experience.